Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00609323 · ClinicalTrials.gov registry record · Phase 2
Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)
A Phase 2 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00609323: Completed Phase 2 study, sponsored by ZARS Pharma.
NCT00609323 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00609323, a Phase 2 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Pliaglis™ (lidocaine and tetracaine) Cream 7%/7% is a topical local anesthetic cream that forms a pliable peel on the skin when exposed to air. When applied to intact skin, Pliaglis provides local dermal analgesia by the release of lidocaine and tetracaine from the peel into the skin. Pliaglis is currently approved in the United States for use on intact skin in adults to provide topical local analgesia for superficial dermatological procedures such as dermal filler injection, pulsed dye laser therapy, and facial laser resurfacing. This study will evaluate lidocaine and tetracaine cream 7%/7% for the treatment of pain associated with postherpetic neuralgia (PHN).
Interventions
- DRUG Placebo
- DRUG lidocaine and tetracaine cream 7%/7%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00609323 record still lists
NCT00609323 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00609323 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00609323 about?
NCT00609323 is a clinical study titled "Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)". Pliaglis™ (lidocaine and tetracaine) Cream 7%/7% is a topical local anesthetic cream that forms a pliable peel on the skin when exposed to air. When applied to intact skin, Pliaglis provides local dermal analgesia by the release of lidocaine and tetracaine from the peel into the skin. Pliaglis is c...
What is the current status of trial NCT00609323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2008-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00609323?
The interventions under investigation include: Placebo (DRUG), lidocaine and tetracaine cream 7%/7% (DRUG).
Who is sponsoring clinical trial NCT00609323?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00609323's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia